Regarding the sequencing of therapy, which statement is true about paclitaxel and platinum-containing regimens?

• A. Paclitaxel should be given before platinum-containing medications to help prevent myelosuppression
• B. Platinum should always be given before paclitaxel
• C. There is no required order between paclitaxel and platinum therapies
• D. They must be given simultaneously

Answer: (A)

Sequencing matters when combining drugs because the timing can influence both how well the cancer is killed and how toxicities emerge. Administering paclitaxel before the platinum-containing agent is common because paclitaxel’s mechanism—stabilizing microtubules and arresting cells in the G2/M phase—sensitizes tumor cells to the DNA-damaging effects of platinum. This synergy means the platinum component can produce greater cytotoxicity within the same cycle, improving overall effectiveness. In practice, this ordering supports delivering the full planned dose and schedule across cycles while managing toxicity, since platinum is a major contributor to hematologic suppression and requires careful monitoring. Other sequencing patterns—giving platinum first or administering them simultaneously—don’t reflect this synergistic approach as consistently in standard regimens.